U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT06834529) titled 'CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma' on Jan. 17.
Brief Summary: This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.
Study Start Date: Jan. 20
Study Type: INTERVENTIONAL
Condition:
Relapsed or Refractory B Cell Leukemia and Lymphoma
Intervention:
GENETIC: CAR2219-T cells
Genetic: CAR2219-T cells Each subject will be infused with single dose of CD2219-CAR-T cells. A classic "3+3" dose escalation will be employed. The low dose is 5x10^5 /kg, the medium dose is 1x10^6 /kg...